The company collaborates with Grifols, a global healthcare company, and has conducted breakthrough research that shows factors in the blood plasma of young mice can reverse brain deficits in normal aging and Alzheimer's disease models in mice. Alkahest's therapies are designed to augment these factors in blood plasma to reverse the detrimental effects of aging in both normal aging and disease models in animals. Clinical studies are currently underway in patients with different types of dementia and other neurodegenerative diseases.